CHI3L1 and Cirrhosis: For the noncirrhotic patients, although the CHI3L1 levels at T0 were approximately 40% lower in the non-LC group than in the LC group, similar patterns of decline were observed, suggesting that DAA treatments effectively reduced liver fibrosis regardless of the cirrhosis status before treatment.